Postprandial triglycerides and blood coagulation

Summary:

Most of our lifetime we spend in the postprandial state. Postprandial triglyceridemia may represent a procoagulant state involving disturbances of both blood coagulation and fibrinolysis, in particular due to elevation of the plasma levels of activated factor VII (VIIa) and plasminogen activator inhibitor (PAI-1). Therefore, disturbances of the hemostatic system might, at least partly, account for by the link between hypertriglyceridemia and coronary heart disease (CHD). - Factor VIIa is the first enzyme of the blood coagulation system and serves a priming function for triggering of the clotting cascade. The coagulant activity of factor VII (VIIc, total activity of factor VII in plasma) was identified as an independent predictor of myocardial infarction in initially healthy middle-aged men, and particularly of fatal coronary events, and both serum cholesterol and triglyceride concentrations correlated positively with the VIIc level. Addition of fat to diet has been consistently shown to cause a rapid conversion of the factor VII zymogen into its active form (VIIa) whereas the concentration of total protein is unaffected. Postprandial activation of factor VII is dependent on lipolytic activity and it is mainly supported by large triglyceride-rich lipoprotein of the VLDL class. Studies in vivo with specific coagulation factor-deficient patients indicate that factor IX is essential for the postprandial activation of factor VII. The basal generation of thrombin seems to be unaffected by increased plasma levels of VIIa. However, since VIIa-tissue factor complex is responsible for the initiation of the coagulation cascade, increased generation of VIIa in the postprandial state would increase the potential for thrombin production in the event of plaque rupture. - Plasminogen activator inhibitor-1 (PAI-1) is the major physiological inhibitor of the plasminogen activators in the circulation and thereby the principal inhibitor of the fibrinolytic system. Postprandial triglyceridemia has been observed in many, not all, studies to increase PAI-1 plasma levels, which would further strengthen the chances of thrombotic occlusion of a vessel after rupture of an atherosclerotic plaque.

Key words:

Factor VII - blood coagulation - plasminogen activator inhibitor-1 (PAI-1) - postprandial triglycerides - alimentary lipemia

References

• 1 Allison B A, Nilsson L, Karpe F, Hamsten A, Eriksson P. Effects of native, triglyceride-enriched and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells.  Arterioscler Thromb Vasc Biol. 19 1354-1360 1999; 
• 2 Asplund-Carlson A, Hamsten H, Wiman B, Carlson L A. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity. Studies in randomly selected normo- and hypertriglyceridemic men.  Diabetologia. 36 817-825 1993; 
• 3 Bauer K A, Kass B L, ten Cate H, Hawiger J J, Rosenberg R D. Factor IX is activated in vivo by the tissue factor mechanism.  Blood. 76 731-736 1990; 
• 4 Bladbjerg E M, Marckmann P, Sandström B, Jespersen J. Non-fasting factor VII coagulant activity (FVII:c) increased by high fat diet.  Thromb Haemost. 71 755-758 1994; 
• 5 Bouma B M, von dem Borne P AK, Meijers J CM. Factor XI and protection of the fibrin clot against lysis - A role for the intrinsic pathway of the coagulation in fibrinolysis.  Thromb Haemost. 80 24-27 1998; 
• 6 Bouma B N, Marx P F, Mosnier L O, Meijers J CM. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U).  Thromb Res. 101 329-354 2001; 
• 7 Broadhurst P, Kelleher C, Hughes L, Imeson J D, Raftery E B. Fibrinogen, factor VII clotting activity and coronary artery disease severity.  Atherosclerosis. 85 169-173 1990; 
• 8 Byrne C D, Wareham N J, Martensz N D, Humphries S E, Metcalfe J C, Grainger D J. Increased PAI activity and PAI-1 antigen ocurring with an oral fat load: associations with PAI-1 genotype and plasma active TGF-β levels.  Atherosclerosis. 140 45-53 1998; 
• 9 Fair D S. Quantitation of factor VII in plasma of normal and warfarin-treated individuals by radioimmunoassay.  Blood. 62 784-791 1983; 
• 10 Green F, Kelleher C, Wilkes H, Temple A, Meade T, Humphries S. A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals.  Arterioscler Thromb. 11 540-546 1991; 
• 11 Genest J, Nguyen N-H, Theroux P, Davignon J, Cohn J S. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.  J Cardiovasc Pharmacol. 35 164-172 2000; 
• 12 Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.  Lancet. 2 3-9 1987; 
• 13 Hamsten A, Wiman B, de Faire U, Blombäck M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction.  N Engl J Med. 313 1557-1563 1985; 
• 14 Hamsten A. Hypertriglyceridaemia, triglyceride-rich lipoproteins and coronary heart disease. In: Betteridge J (Ed). Lipids and lipoproteins. Bailliere's Clinical Endocrinology and Metabolism. 4: 895-922 1990
• 15 Hoffman C, Shah A, Sodums M, Hultin M B. Factor VII activity state in coronary artery disease.  J Lab Clin Med. 111 475-481 1988; 
• 16 Hoffman C J, Miller R H, Lawson W E, Hultin M B. Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease.  J Am Coll Cardiol. 14 941-946 1989; 
• 17 Humphries S E, Lane A, Green F, Cooper J, Miller G. Factor VII coagulant activity and antigen levels in men are determined by interaction between factor VII genotype and plasma triglyceride concentration.  Arterioscler Thromb. 14 193-198 1994; 
• 18 Jastrzebska M, Przybycien K, Cheltowski K, Torbus-Lisiecka B, Kornacewicz-Jach Z, Naruszewicz M. Increased levels of factor VII, fibrinogen and activity of plasminogen activator inhibitor during postprandial tryglyceridemia in patients with ischemic heart disease confirmed by angiography.  Nutr Metab Cardiovasc Dis. 9 33-40 1999; 
• 19 Juhan-Vague I, Pyke S DM, Alessi M C, Jespersen J, Haverkate F, Thompson S G. on behalf of the ECAT Study Group . Fibrinolytic factors and the risk of myocardial infarction on sudden death in patients with angina pectoris.  Circulation. 94 2057-2063 1996; 
• 20 Junker R, Heinrich J, Schulte H, van de Loo J, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men.  Arterioscler Thromb Vasc Biol. 17 1539-1544 1997; 
• 21 Kapur R, Hoffmann C J, Bhushan V, Hultin M B. Postprandial elevation of activated factor VII in young adults.  Arterioscler Thromb Vasc Biol. 16 1327-1332 1996; 
• 22 Kjalke M, Silveira A, Hamsten A, Hedner U, Ezban M. Plasma lipoproteins enhance tissue-factor-independent factor VII activation.  Arterioscler Thromb Vasc Biol. 20 1835-1841 2000; 
• 23 Larsen L F, Bladjerberg E-M, Jerpersen J, Marckmann P. Effects of dietary fat quality and quantity on postprandial activation of blood coagulation factor VII.  Arterioscler Thromb Vasc Biol. 17 2904-2909 1997; 
• 24 Marckmann P, Sandström B, Jespersen J. Dietary effects on circadian fluctuation in human blood coagulation factor VII and fibrinolysis.  Atherosclerosis. 101 225-234 1993; 
• 25 Meade T W, Mellows S, Brozovic M, Miller G J, Chakrabarti R R, North W RS, Haines A P, Stirling Y, Imeson J D, Thompson S G. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study.  Lancet. 2 533-537 1986; 
• 26 Meade T W, North W RS, Chakrabarti R, Stirling Y, Haines A P, Thompson S G. Haemostatic function and cardiovascular death: early results of a prospective study.  Lancet. 1 1050-1054 1980; 
• 27 Meade T W, Ruddock V, Stirling Y, Chakrabarti R, Miller G J. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study.  Lancet. 2 1076-1079 1993; 
• 28 Mennen L I, Schouten E G, Grobbee D E, Kluft C. Coagulation factor VII, dietary fat and blood lipids: a review.  Thromb Haemost. 76 492-499 1996; 
• 29 Mennen L I, de Maat M P, Meijer G, Zock P, Grobee D E, Kok F J, Kluft C, Schouten E G. Postprandial response of activated factor VII in elderly women depends on the R353Q polymorphism.  Am J Clin Nutr. 70 435-438 1999; 
• 30 Miller G J, Martin C J, Mitropoulos K A, Esnouf M P, Cooper J A, Morrissey J H, Howarth D J, Tuddenham E GD. Activation of factor VII during alimentary lipemia occurs in healthy adults and in patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency.  Blood. 87 4187-4196 1996; 
• 31 Miller G J, Martin J C, Mitropoulos K A, Reeves B EA, Thompson R L, Meade T W, Cooper J A, Cruickshank J K. Plasma Factor VII is activated by postprandial triglyceridaemia, irrespective of dietary fat composition.  Atherosclerosis. 86 163-171 1991; 
• 32 Miller G J, Martin J C, Webster J, Wilkes H, Miller N E, Wilkinson W H, Meade T W. Association between fat intake and factor VII coagulant activity - a predictor of cardiovascular mortality.  Atherosclerosis. 101 225-234 1993; 
• 33 Miller G J. Postprandial lipemia and haemostatic factors.  Atherosclerosis. 141 S47-S51 1998; 
• 34 Miller G J. Postprandial lipid metabolism and thrombosis.  Proc Nutr Soc. 56 739-744 1997; 
• 35 Mitropoulos K A, Miller G J, Martin J C, Reeves B EA, Cooper J. Dietary fat induces changes in factor VII coagulant activity through effects on plasma free stearic acid concentration.  Arterioscler Thromb. 14 214-222 1994; 
• 36 Mitropoulos K S, Miller G J, Watts G F, Durrington P N. Lipolysis of triglyceride-rich lipoproteins activates coagulant factor XII: a study in familial lipoprotein-lipase deficiency.  Atherosclerosis. 95 119-125 1992; 
• 37 Mitropoulos K A, Reeves B EA, Miller G J. The activation of factor VII in citrated plasma by charged long-chain saturated fatty acids at the interface of large triglyceride-rich lipoproteins.  Blood Coag Fibrinol. 4 943-951 1993; 
• 38 Mitropoulos K A, Reeves B EA, O'Brien D P, Cooper J A, Martin J C. The relationship between factor VII coagulant activity and factor XII activation induced in plasma by endogenous or exogenously added contact surface.  Blood Coag Fibrinol. 4 223-234 1993a; 
• 39 Moor E, Silveira A, van't Hooft F, Suontaka A M, Eriksson P, Blombäck M, Hamsten A. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype.  Arterioscler Thromb Vasc Biol. 15 655-664 1995; 
• 40 Morrissey J H, Macik B G, Neuenschwander P F, Comp P C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation.  Blood. 81 734-744 1993; 
• 41 Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity.  Arterioscler Thromb. 12 19-27 1992; 
• 42 Nørdoy A, Bønaa K H, Sandset P M, Hansen J-B, Nilsen H. Effect of w-3 fatty acids and Simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia.  Arterioscler Thromb Vasc Biol. 20 259-265 2000; 
• 43 Østerud B, Rapaport S I. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation.  Proc Natl Acad Sci USA. 74 5260-5264 1977; 
• 44 Patsch J R, Miesenböck G, Hopferwieser T, Mühlberger V, Knapp E, Dunn J K, Gotto A M, Patsch W. The relationship of triglyceride metabolism and coronary artery disease. Studies in the postprandial state.  Atheroscler Thromb. 12 1336-1345 1992; 
• 45 Radcliffe R, Nemerson Y. Activation and control of factor VII by activated factor X and thrombin. Isolation and characterization of a single chain form of factor VII.  J Biol Chem. 250 388-395 1975; 
• 46 Ryu J E, Howard G, Craven T E, Bond M G, Hagaman A P, Crouse J. Postprandial triglyceridemia and carotid atherosclerosis in middle-aged subjects.  Stroke. 23 823-828 1992; 
• 47 Salomaa V, Rasi V, Pekkanen J, Jauhiainen M, Vahtera E, Pietinen P, Korhonen H, Kuulasmaa K, Elnholm C. The effects of saturated fat and n-6 polyunsaturated fat on postprandial lipemia and hemostatic activity.  Atherosclerosis. 103 1-11 1993; 
• 48 Sanders T A, Miller G J, de Grassi T, Yahia N. Post-prandial activation of coagulant factor VII by long-chain dietary fatty acids.  Thromb Haemost. 76 369-371 1996; 
• 49 Schneiderman J, Sawdey M S, Keeton M R, Bordin G M, Bernstein E F, Dilley R B, Loskutoff D J. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries.  Proc Natl Acad Sci USA. 89 6998-7002 1992; 
• 50 Seligsohn U, Kasper C K, Østerud B, Rapaport S I. Activated factor VII: presence in factor IX concentrates and persistence in the circulation after infusion.  Blood. 53 828-837 1979; 
• 51 Silveira A, Green F, Karpe F, Blombäck M, Humphries S, Hamsten A. Elevated levels of factor VII activity in the postprandial state: effect of the factor VII Arg-Gln polymorphism.  Thromb Haemost. 72 734-739 1994; 
• 52 Silveira A, Karpe F, Blombäck M, Steiner G, Walldius G, Hamsten A. Activation of coagulation factor VII during alimentary lipemia.  Arterioscler Thromb. 14 60-69 1994a; 
• 53 Silveira A, Karpe F, Johnsson H, Bauer K A, Hamsten A. In vivo demonstration that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway.  Arterioscler Thromb Vasc Biol. 16 1333-1339 1996; 
• 54 Suzuki T, Yamauchi K, Matsushita T, Furumichi T, Furui H, Tsuzuki J, Saito H. Elevation of factor VII activity and mass in coronary artery disease of varying severity.  Clin Cardiol. 14 731-736 1991; 
• 55 ten Cate H, Bauer K A, Levi M, Edgington T S, Sublett R D, Barzegar S, Kass B L, Rosenberg R D. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor.  J Clin Invest. 92 1207-1212 1993; 
• 56 Wildgoose P, Nemerson Y, Hansen L L, Nielsen F E, Glazer S, Hedner U. Measurement of basal levels of factor VIIa in hemophilia A and B patients.  Blood. 80 25-28 1992;